4,789
Participants
Start Date
March 27, 2017
Primary Completion Date
December 24, 2019
Study Completion Date
December 20, 2023
Ad26.ZEBOV
0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
MVA-BN-Filo
0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
rVSVΔG-ZEBOV-GP
1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Placebo
0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
rVSV boost
1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Centre national de formation et de recherche en santé rurale (Maferyniah), Conakry
Landreah, Conakry
The Redemption Hospital, Monrovia
Centre pour le Développement des Vaccins (CVD), Bamako
University Clinical Research Center (UCRC), Bamako
Mambolo Clinic, Kapesseh
Partnership for Research on Ebola Virus in Liberia (PREVAIL)
NETWORK
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
London School of Hygiene and Tropical Medicine
OTHER
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
National Institute of Allergy and Infectious Diseases (NIAID)
NIH